{
  "id": "5c915a8becadf2e73f000009",
  "type": "factoid",
  "question": "Which was the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body?",
  "ideal_answer": "The first approved tumor treatment using a common biomarker rather than specified tumor locations in the body was Keytruda, which is a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29209918"
  ],
  "snippets": [
    {
      "text": "On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Keytruda"
}